Stereotactic radiotherapy of intracranial tumor beds on a ring-mounted Halcyon LINAC.

PURPOSE: This study sought to evaluate the feasibility and efficacy of the Halcyon Ring Delivery System (RDS) for delivering stereotactic radiotherapy (SRT) treatments for intracranial tumors beds. METHODS: Ten previously treated brain SRT patients for 30 Gy in five fractions with non-coplanar HyperArc plans on TrueBeam (6MV-FFF) were replanned on Halcyon (6MV-FFF) using the same number of arcs and Eclipse's AcurosXB dose engine. Plan quality evaluation metrics per SRT protocol included: PTV coverage, GTV dose (minimum and mean), target conformity indices (CI), heterogeneity index (HI), gradient index (GI), maximum dose 2 cm away from the PTV (D2cm), and doses to organs-at-risk (OAR). Additionally, patient-specific quality assurance (QA) results and beam-on-time (BOT) were analyzed. RESULTS: The Halcyon RDS provided highly conformal SRT plans for intracranial tumor beds with similar dose to target. When benchmarked against clinically delivered HyperArc plans, target coverage, CI(s) and HI were statistically similar. The Halcyon plans saw no statistical difference in maximum OAR doses to the brainstem, spinal cord, and cochlea. Due to the machine's coplanar geometry, the Halcyon plans showed a decrease in optic pathway dose (0.75 Gy vs. 2.08 Gy, p = 0.029). Overall, Halcyon's coplanar geometry resulted in a larger GI (3.33 vs. 2.72, p = 0.008) and a larger D2cm (39.59% vs. 29.07%, p < 0.001). In this cohort, multiple cases had the PTV and the optic pathway in the same axial plane. In one such instance, the PTV was <2 cm away from the optic pathway but even at this close proximity OAR, Halcyon still adequately spared the optic pathway. Additionally, the Halcyon's geometry provided slightly larger amount of normal brain dose receiving 24.4 Gy (8.99 cc vs. 7.36 cc) and 28.8 Gy (2.9 cc vs. 2.5 cc), although statistically insignificant. The Halcyon plans achieved similar delivery accuracy, quantified by patient-specific QA results evaluated with a 2%/2 mm gamma criteria (99.42% vs. 99.70%). For both plans, independent Monte Carlo second checks calculation agreed within 1%. Average Halcyon BOT was slightly higher by 0.35 min (p = 0.045), however, due to the one-step patient set-up and verification overall estimated treatment times on Halcyon were lower compared to HyperArc treatments (7.61 min vs. 10.26 min, p < 0.001). CONCLUSIONS: When benchmarked against clinically delivered HyperArc treatments, the Halcyon brain SRT plans provided similar plan quality and delivery accuracy but achieved faster overall treatment times. We have started treating select brain SRT patients on the Halcyon RDS for patients having tumor beds greater than 1 cm in diameter with the closest OAR distance of greater than 2 cm away from the target. We recommend other clinics to consider commissioning SRT treatments on their Halcyon systems-allowing including remote Halcyon-only clinics to provide exceptionally high-quality therapeutic brain SRT treatments to an otherwise underserved patient cohort.

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.

OBJECTIVES: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial compared hematopoietic stem cell transplant to CYC treatment in patients with early SSc with progressive skin and lung or kidney involvement. Here we describe lymphocyte phenotype abnormalities at study entry and the relation to prior DMARD therapy. METHODS: Lymphocyte subsets (n = 26) measured by flow cytometry were compared in 123 heathy controls and 71 SCOT participants, including those given (n = 57) or not given (n = 14) DMARDs within 12 months of randomization. RESULTS: Compared with healthy controls, individuals with SSc showed significant reductions in central memory CD8 T cells, activated total and CD4 T cells, γ/δ T cells, memory B cells, myeloid and plasmacytoid dendritic cells and FOXP3+CD25+ Treg cells and increases in naïve CD4 T cells, effector memory CD4 T cells and effector CD8 T cells. A greater bias towards a IL-4+ Th2/T cytotoxic 2 (Tc2) phenotype based on the Th2:Th1 CD4 ratio and Tc2:Tc1 CD8 T cells was also found. Notably, no difference in any lymphocyte subset was observed between those given or not given prior DMARDs. CONCLUSIONS: In patients with early, severe SSc, significant lymphocyte subset abnormalities were observed. Prior treatment with immunosuppressive therapy did not impact the immunophenotype, suggesting that lymphocyte disturbances in scleroderma appeared to be due to the disease itself. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT00114530.

Dynamic conformal arcs-based single-isocenter VMAT planning technique for radiosurgery of multiple brain metastases.

Multiple small beamlets in the delivery of highly modulated single-isocenter HyperArc VMAT plan can lead to dose delivery errors associated with small-field dosimetry, which can be a major concern for stereotactic radiosurgery for multiple brain lesions. Herein, we describe and compare a clinically valuable dynamic conformal arc (DCA)-based VMAT (DCA-VMAT) approach for stereotactic radiosurgery of multiple brain lesions using flattening filter free beams to minimize this effect. Original single-isocenter HyperArc style VMAT and DCA-VMAT plans were created on 7 patients with 2 to 8 brain lesions (total 35 lesions) for 10 MV- flattening filter free beam. 20 Gy was prescribed to each lesion. For identical planning criteria, DCA-VMAT utilizes user-controlled field aperture shaper before VMAT optimization. Plans were evaluated for conformity and target coverage, low- and intermediate dose spillages to brain volume that received more than 30% (V30%) and 50% (V50%) of prescription dose. Additionally, mean brain dose, V8, V12 and maximal dose to adjacent organs-at-risk (OAR) including hippocampi were reported. Total monitor units, beam modulation factor, treatment delivery efficiency, and accuracy were recorded. Comparing with original VMAT, DCA-VMAT plans provided similar tumor dose, target coverage and conformity, yet tighter radio-surgical dose distribution with lower dose to normal brain V30% (p = 0.009), V50% (p = 0.05) and other OAR including lower dose to hippocampi. Lower total number of monitor units and smaller beam modulation factor reduced beam on time by 2.82 min (p < 0.001), on average (maximum up to 3.8 min). Beam delivery accuracy was improved by 8%, on average (p < 0.001) and maximum up to 13% in some cases for DCA-VMAT plans. This novel DCA-VMAT approach provided excellent plan quality, reduced dose to normal brain, and other OAR while significantly reducing beam-on time for radiosurgery of multiple brain lesions-improving patient compliance and clinic workflow. It also provided less MLC modulation through the targets-potentially minimizing small field dosimetry errors as demonstrated by quality assurance results. Incorporating DCA-based VMAT optimization in HyperArc module for radiosurgery of multiple brain lesions merits future investigation.